Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08AWI
|
||||
| Former ID |
DCL000937
|
||||
| Drug Name |
PRX-00023
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Severe mood disorders [ICD9: 296; ICD10:F30-F39] | Discontinued in Phase 2 | [1] | ||
| Company |
Epix
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H38N4O3S
|
||||
| Canonical SMILES |
CC(=O)NC1=CC=CC(=C1)N2CCN(CC2)CCCCNS(=O)(=O)CC3CCCCC3
|
||||
| InChI |
1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
|
||||
| InChIKey |
SPWZXWDPAWDKQE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 740873-06-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Modulator | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.